Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study

Area of Science:

• Pharmacogenomics
• Molecular Diagnostics
• Oncology

Background:

• Metastatic colorectal cancer (mCRC) treatment often involves irinotecan.
• Irinotecan efficacy and toxicity are influenced by UDP glucuronosyltransferase 1A1 (UGT1A1) enzyme activity.
• Genetic variations in UGT1A1 can predict patient response and risk of adverse drug reactions.

Purpose of the Study:

• To analyze clinical, economic, and regulatory data for the Invader UGT1A1 Molecular Assay.
• To identify challenges and gaps in the evidence base for translating UGT1A1 testing into clinical practice.
• To assess the potential societal impact of UGT1A1 testing in irinotecan prescribing.

Main Methods:

• Descriptive analysis of data from the Evaluation Data for Assessing Personalized Medicine Translation (EDAPT) evidence base.
• Review of clinical application, economic, and regulatory information related to the UGT1A1 assay.
• Examination of issues concerning the adoption of UGT1A1 testing in clinical practice.

Main Results:

• The UGT1A1 Molecular Assay, designed to predict irinotecan-related adverse drug reactions, received US FDA approval.
• Data on the test's clinical utility, economic factors, and regulatory status were compiled.
• Gaps in the evidence base and challenges in clinical adoption were identified.

Conclusions:

• The UGT1A1 assay represents a step towards personalized medicine in mCRC treatment.
• Further evidence and strategies are needed to facilitate the widespread adoption of UGT1A1 testing.
• Societal implications of pharmacogenetic testing for irinotecan therapy warrant consideration.